SCHEMBL3344513

SCHEMBL3344513

CCCCCCCCC(O)C(O)C(O)CCCCCCCC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPHK1 Q9NYA1 2/20 0.62
CYP2D6 P10635 2/20 0.58
LMNA P02545 2/20 0.58
GMNN O75496 1/20 0.58
POLB P06746 1/20 0.58
THPO P40225 1/20 0.58
MTOR P42345 1/20 0.58
BLM P54132 1/20 0.58
KDM4E B2RXH2 1/20 0.58
TP53 P04637 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
MAPT P10636 1/20 0.58
CETP P11597 1/20 0.58
HTT P42858 1/20 0.58
UBE2N P61088 1/20 0.58
GPR84 Q9NQS5 7/20 0.50
FFAR1 O14842 1/20 0.50
TRPV1 Q8NER1 1/20 0.46
TRPA1 O75762 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL139953 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL27963355 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL13825654 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL142855 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL7756046 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL10605211 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL2385582 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL10607850 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL136612 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB
SCHEMBL10606337 1.00 SPHK1 (0.62) SPHK1CYP2D6LMNAGMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-60081193-A None JP disclosed
CN-117205156-A Pressure-sensitive multivesicular liposome for intervening in altitude pulmonary edema, and preparation method and application thereof 徐州医科大学 2023-12-12 CN disclosed
EP-1600449-B1 Process for producing an ester, acetal, ketal, ether or alkyl glycoside KAO CORP (JP) 2010-12-29 EP disclosed
US-20100152244-A1 SELF-EMULSIFYING FORMULATION OF TIPRANAVIR FOR ORAL ADMINISTRATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-06-17 US disclosed
EP-2164465-A1 SELF-EMULSIFYING FORMULATION OF TIPRANAVIR FOR ORAL ADMINISTRATION Boehringer Ingelheim International GmbH (DE) 2010-03-24 EP disclosed
WO-2008142090-A1 SELF-EMULSIFYING FORMULATION OF TIPRANAVIR FOR ORAL ADMINISTRATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-11-27 WO disclosed
EP-1600449-A1 Process for producing an ester, acetal, ketal, ether or alkyl glycoside Kao Corporation (JP) 2005-11-30 EP disclosed
EP-0980869-B1 ALUMINUM COMPOUNDS AND USE THEREOF KAO CORP (JP) 2005-06-08 EP disclosed
US-6207845-B1 ORGANOALUMINUM COMPOUND; ACID CATALYST KAO CORPORATION (JP) 2001-03-27 US disclosed
EP-0980869-A1 ALUMINUM COMPOUNDS AND USE THEREOF Kao Corporation (JP) 2000-02-23 EP disclosed
EP-0138558-B1 PHOSPHOLIPIDS AND THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 1989-07-19 EP disclosed
US-4775758-A Phospholipids TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1988-10-04 US disclosed
JP-S6081193-A PHOSPHOLIPID TAKEDA CHEM IND LTD 1985-05-09 JP disclosed
EP-0138558-A2 Phospholipids and their production and use Takeda Chemical Industries, Ltd. (JP) 1985-04-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152244-A1 SELF-EMULSIFYING FORMULATION OF TIPRANAVIR FOR ORAL ADMINISTRATION TTPA, CETP, TYMS SPHK1 65/4885CYP2D6 39/4885LMNA 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.